Fallopian Tube Clinical Trials in Birmingham, Alabama
12 recruitingBirmingham, Alabama
Showing 1–12 of 12 trials
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled164 locationsNCT06824467
Recruiting
Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 2
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 2
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian CancerEndometrial CancerFallopian Tube Cancer+1 more
Corcept Therapeutics270 enrolled49 locationsNCT06906341
Recruiting
Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Regeneron Pharmaceuticals220 enrolled50 locationsNCT06787612
Recruiting
Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ovarian CarcinomaOvarian High Grade Serous AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+6 more
NRG Oncology880 enrolled676 locationsNCT06580314
Recruiting
Phase 1Phase 2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ovarian CancerEndometrial CancerMetastatic Cancer+6 more
Artios Pharma Ltd442 enrolled79 locationsNCT04657068
Recruiting
Phase 1Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Endometrial CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer+2 more
Regeneron Pharmaceuticals890 enrolled51 locationsNCT03564340
Recruiting
Phase 2
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian CancerPrimary Peritoneal CancerFallopian Tube
University of Alabama at Birmingham70 enrolled9 locationsNCT04606914
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444